A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study on Safety, Tolerability and Pharmacokinetics of SHR0410 in Hemodialysis Subjects With Moderate to Severe Pruritus
Latest Information Update: 06 May 2022
At a glance
- Drugs SHR-0410 (Primary)
- Indications Pruritus
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 21 May 2020 Status changed from not yet recruiting to recruiting.
- 26 Mar 2020 New trial record